Reuters
05 Nov 2026, 11:58 UTC · 2w ago
Weak US sentiment hurts dietary supplement sales, offsetting broader growth, Novonesis CEO says
Impact · against what's priced in
Novonesis faces a potential revenue headwind as weak US consumer sentiment drags down dietary supplement sales, offsetting growth in other segments. This creates a risk of downward revisions to FY2026 revenue estimates.
- NVON−0.40
No priced-in read yet
- In context





